MYC Program

About Interdict

Interdict Bio is a private, pre-clinical stage biotech founded in 2022 and based in Cambridge, USA, developing a revolutionary small molecule modality called Interdictors™. Its platform targets the ribosome to selectively inhibit the synthesis of pathogenic proteins, enabling it to address validated but elusive targets like intrinsically disordered proteins (e.g., MYC) and aggregation-prone proteins. The lead program targeting MYC-dependent cancers is in IND-enabling studies, positioning the company to potentially open new therapeutic frontiers in oncology and neurodegeneration.

Therapeutic Areas